HeartBeam Inc. Receives FDA Clearance for Innovative Cable-Free ECG System
HeartBeam Inc. has achieved FDA 510(k) clearance for its pioneering, credit card-sized, cable-free ECG system, enhancing remote arrhythmia detection and cardiac care accessibility.
HeartBeam Inc. (NASDAQ: BEAT) has reached a significant milestone with the FDA 510(k) clearance of its innovative, credit card-sized, cable-free ECG system, designed for arrhythmia detection. This advancement represents a leap forward in remote cardiac care, enabling patients to record and upload a 30-second ECG for physician review through an app-guided system.
The clearance not only facilitates the launch of an Early Access Program for early adopters and providers but also paves the way for future developments in cardiac care technology. These include 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring, aiming to provide continuous, predictive insights outside traditional clinical settings.
HeartBeam's vision to revolutionize cardiac care by offering actionable heart intelligence wherever the patient is marks a transformative step in managing cardiac health. The company's technology, supported by 13 U.S. and 4 international patents, is set to redefine the approach to detecting and managing acute cardiac conditions and trends outside medical facilities.